Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1365 - 1365
Опубликована: Дек. 3, 2024
Objectives:
Accumulating
evidence
has
confirmed
the
efficacy
and
safety
of
COVID-19
vaccines
against
SARS-CoV-2
infection.
However,
effect
vaccination
on
immuno-virological
parameters
in
people
with
HIV
(PWH)
is
uncertain.
Methods:
A
total
372
PWH
treated
at
Beijing
Ditan
Hospital
were
included.
Unvaccinated
matched
1:3
vaccinated
using
a
propensity
score
matching
algorithm.
Differences
markers
between
groups
analyzed.
The
Wilcoxon
signed
rank
test
was
used
to
for
changes
CD4
CD8
counts
viral
load
over
two
months
around
vaccination.
In
addition,
we
investigated
long-term
HIV-related
different
dose
entire
population.
Results:
Vaccinated
had
higher
CD4/CD8
ratio
(0.64
(0.49,
0.78)
vs.
0.80
(0.56,
1.03),
p
=
0.037)
than
unvaccinated
within
two-month
window
after
third
dose.
There
337
who
received
vaccination,
73.9%
(n
249)
three
doses
vaccine.
We
observed
transient
increase
count
especially
second
(CD4
count:
583.5
(428.5,
706.8)
618.0
(452.0,
744.0),
0.018;
ratio:
0.70
(0.50,
0.91)
0.71
(0.53,
0.96),
<
0.001))
575.5
(435.5,
717.0)
577.5
(440.8,
754.8),
0.001;
(0.52,
0.93)
0.79
1.00),
0.001)).
Recent
ratios
lower
but
remained
before
PWH.
no
negative
load.
Conclusions:
enhanced
cellular
immune
response
induced
by
may
diminish
time
return
normal
levels.
adverse
SSRN Electronic Journal,
Год журнала:
2024,
Номер
unknown
Опубликована: Янв. 1, 2024
The
lifting
of
the
long-lasting
zero-COVID
policy
in
China
December
2022
was
immediately
followed
by
a
national
surge
Omicron
variants
SARS-CoV-2
that
nearly
exhausted
country's
healthcare
system.
While
monovalent
inactivated
vaccines
received
majority
Chinese
population
were
not
protective
against
infection
and
clinical
diseases,
their
utility
preventing
death
severe
outcomes
among
hospitalized
patients
remains
unclear.
We
collected
retrospective
prospective
data
on
baseline
characteristics,
vaccination
history,
outcome
patient
three
hospitals
who
admitted
during
surge.
Among
862
with
information,
360
(41.8%)
at
least
one
dose
COVID
vaccine
only
214
(24.8%)
≥
3
doses.
effectiveness
(VE)
estimated
to
be
74%
(95%
CI:
43%,
88%)
65%
45%,
78%)
disease
(use
Mechanic
Ventilator,
ICU
or
death),
reference
unvaccinated.
two
most
widely
used
China,
BBIBP-CorV
(Sinopharm)
CoronaVac
(Sinovac),
showed
similar
effectiveness,
though
doses
former
appeared
slightly
more
effective
death,
80%
8%,
96%)
vs.
66%
18%,
86%).
observe
no
decay
VE
after
year
since
last
dose.
A
delay
about
6
months
between
2nd
3rd
associated
moderately
lower
protection
death.
being
replaced
bivalent
vaccines,
can
viable
option
for
resource-limited
settings.
Vaccines,
Год журнала:
2024,
Номер
12(8), С. 840 - 840
Опубликована: Июль 25, 2024
(1)
Background:
The
global
coronavirus
disease
2019
vaccination
adapts
to
protect
populations
from
emerging
variants.
This
communication
presents
interim
findings
the
new
Omicron
XBB.1.16-adapted
PHH-1V81
protein-based
vaccine
compared
an
XBB.1.5-adapted
mRNA
against
various
acute
respiratory
syndrome
2
(SARS-CoV-2)
strains.
(2)
Methods:
In
a
Phase
IIb/III
pivotal
trial,
adults
previously
vaccinated
with
primary
scheme
and
at
least
one
booster
dose
of
EU-approved
randomly
received
either
or
BNT162b2
XBB.1.5
as
single
dose.
efficacy
endpoint
assessed
neutralization
titers
XBB.1.16
variant
day
14.
Secondary
endpoints
evaluated
cellular
immunity
different
Safety
comprised
solicited
reactions
up
7
post-vaccination
serious
adverse
events
until
cut-off
date
analysis.
Changes
in
humoral
responses
were
by
pseudovirion-based
virus
assays.
(3)
Results:
At
date,
immunogenicity
assessments
included
599
participants.
Both
boosters
elicited
neutralizing
antibodies
XBB.1.16,
XBB.1.5,
JN.1,
inducing
higher
response
for
all
PHH-1V8
triggers
superior
antibody
XBB
variants
vaccine.
A
subgroup
analysis
consistently
revealed
across
age
groups,
SARS-CoV-2
infection
history,
number
prior
shots.
safety
(n
=
607)
14
visit
favorable
profiles
without
any
vaccine-related
events.
(4)
Conclusions:
demonstrates
superiority
on
non-inferiority
JN.1
profile
lower
reactogenicity,
confirming
its
potential
candidate.
Vaccines,
Год журнала:
2024,
Номер
12(12), С. 1365 - 1365
Опубликована: Дек. 3, 2024
Objectives:
Accumulating
evidence
has
confirmed
the
efficacy
and
safety
of
COVID-19
vaccines
against
SARS-CoV-2
infection.
However,
effect
vaccination
on
immuno-virological
parameters
in
people
with
HIV
(PWH)
is
uncertain.
Methods:
A
total
372
PWH
treated
at
Beijing
Ditan
Hospital
were
included.
Unvaccinated
matched
1:3
vaccinated
using
a
propensity
score
matching
algorithm.
Differences
markers
between
groups
analyzed.
The
Wilcoxon
signed
rank
test
was
used
to
for
changes
CD4
CD8
counts
viral
load
over
two
months
around
vaccination.
In
addition,
we
investigated
long-term
HIV-related
different
dose
entire
population.
Results:
Vaccinated
had
higher
CD4/CD8
ratio
(0.64
(0.49,
0.78)
vs.
0.80
(0.56,
1.03),
p
=
0.037)
than
unvaccinated
within
two-month
window
after
third
dose.
There
337
who
received
vaccination,
73.9%
(n
249)
three
doses
vaccine.
We
observed
transient
increase
count
especially
second
(CD4
count:
583.5
(428.5,
706.8)
618.0
(452.0,
744.0),
0.018;
ratio:
0.70
(0.50,
0.91)
0.71
(0.53,
0.96),
<
0.001))
575.5
(435.5,
717.0)
577.5
(440.8,
754.8),
0.001;
(0.52,
0.93)
0.79
1.00),
0.001)).
Recent
ratios
lower
but
remained
before
PWH.
no
negative
load.
Conclusions:
enhanced
cellular
immune
response
induced
by
may
diminish
time
return
normal
levels.
adverse
